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Abstract
Use of arginine vasopressin in the management of refractory
vasodilatory shock has been associated with development of
ischaemic skin lesions. Because of the increasing popularity of
arginine vasopressin, it is important to evaluate its effects on
microcirculatory blood flow. Such studies are crucial if we are to
appreciate the microcirculatory consequences of our various
resuscitation strategies. However, methodological issues must
always be considered because they can significantly influence
interpretation of the results. Some aspects of use of laser Doppler
to evaluate the microcirculation are reviewed within the context of
recent findings presented by Luckner and coworkers in this issue
of Critical Care.
Introduction
Arginine vasopressin (AVP) is increasingly used in the
management of refractory vasodilatory shock. Indeed, it was
recently incorporated into the recommendations (grade IIB)
proposed by the American Heart Association for treatment of
refractory septic shock [1] and the guidelines of the Surviving
Sepsis Campaign (grade E) [2]. However, although the global
haemodynamic effects of AVP are relatively well described, its
effects on the microcirculation are still largely unknown.
In this issue of Critical Care, Luckner and coworkers [3]
present an original study in which they evaluated skin micro-
vascular blood flow, using laser Doppler fluxmetry, before and
after AVP infusion in patients with refractory septic shock.
They report that AVP infusion did not impair forearm skin
perfusion compared with norepinephrine alone. The authors
intended to explore further the results of two of their previous
studies: a retrospective analysis [4], in which they reported a
30.2% rate of ischaemic skin lesions with AVP infusion; and a
prospective controlled trial [5] that found no difference in the
incidence of such lesions between a group of patients
treated with AVP plus norepinephrine and patients treated
with norepinephrine alone. Of note, it is difficult to draw
conclusions regarding the safety of AVP administration on the
basis of the latter study because the dose of norepinephrine
received by the patients in the AVP/norepinephrine group
was half that in the other group.
As mentioned by the authors, their results presented in this
issue are in striking contrast to those of several published
physiological experiments on the topic. Indeed, animal and
human studies [6-9] have revealed significant dose-depen-
dant impairment in skin blood flow with AVP. Indeed, the skin
microvasculature is considered to be a vascular bed that is
rather sensitive to AVP [10]. Accordingly, the results of the
study presented by Luckner and coworkers are somewhat
unexpected, and some methodological issues might account
for the discrepancies.
Technical issues: laser Doppler fluxmetry
It is important to note the technical limitations of laser Doppler.
Laser Doppler fluxmetry only provides an estimate of the
average blood flow in a given volume of tissue; this volume can
vary according to its intrinsic refractive properties. Multiple
individual and environmental factors, including haemoglobin
level and temperature, can also influence the results of laser
Doppler fluxmetry [11]. Moreover, laser Doppler fluxmetry does
not take into account the type of microvessels under study,
their morphology, the direction of flow and, more importantly,
the heterogeneity of perfusion; the latter is a key component in
the study of microcirculation, especially in sepsis. More
specifically, the biological zero, which can represent up to 80%
of the total laser Doppler fluxmetry signal, can be modified
during ischaemia/reperfusion procedures because it is
influenced by vasodilatation [12]. Therefore, various authors
Commentary
Skin microcirculation and vasopressin infusion: 
a laser Doppler study
Francis Bernard1, Alain Vinet2,3 and Colin Verdant1,3
1Intensive Care Service, Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montreal, Quebec, Canada
2Department of Physiology and Institute of Biomedical Engineering, Université de Montréal, Montreal, Quebec, Canada
3Hôpital du Sacré-Coeur de Montréal Research Center, Montreal, Quebec, Canada
Corresponding author: Colin Verdant, c-verdant@crhsc.rtss.qc.ca
Published: 29 March 2006 Critical Care 2006, 10:135 (doi:10.1186/cc4884)
This article is online at http://ccforum.com/content/10/2/135
© 2006 BioMed Central Ltd
See related research by Luckner et al. in this issue [http://ccforum.com/content/10/2/R40]Page 2 of 2
(page number not for citation purposes)
Critical Care    Vol 10 No 2 Bernard et al.
have suggested that the biological zero should always be taken
into account when red blood cell flux is measured in the skin
using laser Doppler fluxmetry [12]. Finally, measurement of
differential perfusion is impeded by the rather small signal and
oscillatory pattern of basal cutaneous microcirculation [13]. In
addition, it is worth noting that vasomotion patterns are highly
dependant on probe location relative to the tissue of interest
[14]. This could explain, to some extent, the considerable
difference reported in baseline vasomotion between groups.
These technical issues account for the substantial short-term
variability in laser Doppler fluxmetry measurements [15].
Hence, it is apparent that relatively large observed changes or
large sample sizes are needed to detect statistically significant
differences between groups.
Statistical issues: power calculation and variance
The power of a study is a measure of its ability to detect a
statistical difference when it truly exists; it is particularly
important to bear this in mind when interpreting studies that
return negative findings. The calculated power of the study
reported by Luckner and coworkers is approximately 40%,
considering the observed difference in primary outcome (area
under the curve of the laser Doppler fluxmetry signal)
between the two groups. This means that there is a 60%
chance that a true difference will remained undetected. With
only three additional patients in each group (assuming the
same difference in variance between groups) the study would
identify a significant difference in microvascular blood flow
perfusion and lead to the conclusion that AVP has, in fact, a
considerable deleterious impact on skin microcirculation.
Finally, the important variance in AVP response (8.56 in the
AVP group versus 3.25 in the norepinephrine group; data
provided by Luckner and coworkers) suggests that AVP had
rather heterogeneous effects from patient to patient and that
other factors (e.g. interindividual variability in sensitivity to
AVP stimulation, endogenous AVP level, relative adrenal
insufficiency, among others) could have played a role.
Conclusion
Luckner and colleagues [3] are to be commended for their
pioneering work on the microcirculatory effects of AVP. Such
studies are essential if we are to understand better the micro-
circulatory consequences of our resuscitation strategies.
However, this work should be duplicated, and we should
exercise caution interpreting these results as reassurance that
AVP is devoid of adverse microcirculatory side effects. Further
work examining different microcirculatory beds and using
different measurement tools to assess microcirculation will
improve our knowledge of the role of AVP in resuscitation.
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